FansUnite Entertainment Enters Partnership with Global Gaming Leader Pinnacle Solutions

Pinnacle will provide the B2B Chameleon Gaming Platform with the most comprehensive esports data and odds feed

FansUnite Entertainment Inc. (CSE: FANS) (OTC: FUNFF) ("FansUnite" or the "Company"), a technology company providing leading online gaming solutions, is pleased to announce its latest partnership with Pinnacle Solutions ("Pinnacle"), a global leader in online sports betting.

FansUnite is excited to announce its partnership with Pinnacle to incorporate Pinnacle's new esports data and odds feed into its Chameleon Gaming Platform. The partnership is part of its strategic plan to collaborate with the best data providers for its esports betting offering. Through Pinnacle's partnership with GRID Esports, they gain direct access to GRID's contracts with esports leagues and tournaments, making it the best data source for many major esports events. In partnering with Pinnacle, FansUnite can now offer the best odds on esports bets for its Chameleon Gaming Platform partners, giving it a competitive advantage over other turnkey B2B esports betting products.

"We aim to partner with the leading companies in the industry to provide the best product and options to our customers using the Chameleon Platform. With Pinnacle's addition and their relationship with GRID Esports, we continue to add the best esports betting data available with the most markets and the best odds. It's exciting to be the first to offer Pinnacle Solution' service, and we are honoured they chose to work with us," stated FansUnite CEO Scott Burton.

"The next step is to effectively market the Chameleon Gaming Platform to sportsbooks," continued Scott Burton. "We want to ramp up our B2B segment and get a guaranteed licensing fee when sportsbooks use our services. In addition, we generate additional income as our partners grow as we share in a percentage of the net gaming revenue giving us unlimited upside revenue potential. Partnering with Pinnacle will help take our B2B esports solution to a new level."

Pinnacle's CEO Paris Smith added, "We are really excited to announce this partnership with FansUnite. Pinnacle Solution is going from strength to strength and it's great to see our product getting out there and enhancing the betting experience for customers around the world. We are always focused on getting the most value out of our partnerships for us and our partners. Our deal with FansUnite will certainly add to our experience as a supplier and we are really looking forward to working closely with their team and helping them achieve their goals."

"Our B2B strategy is one that is built on laying solid foundations. Our continued growth, which includes deals like this, is a clear sign that we are working hard to build on our already impressive offering and keep leading the way for others to follow. Whether it's the odds, the risk management, the data, we have the complete package as well as a best-in-class service to match."

About FansUnite Entertainment Inc.

FansUnite is a global sports and entertainment company, focusing on technology related to regulated and lawful online gaming and other related products. FansUnite has produced a one of a kind complete iGaming platform, with a sports and esports focus geared for the next generation of online bettors and casino players. The platform includes products for pre-match betting, in-play betting, daily fantasy, content and a certified RNG to produce casino style chance games. The platform operates multiple B2C brands and B2B software for the online gambling industry. FansUnite also looks to acquire technology platforms and assets with high-growth potential in new or developing markets.

About Pinnacle Solution

Pinnacle Solution offers a comprehensive B2B sportsbook service built on the foundation of unrivalled risk management expertise and the unique ability to leverage Pinnacle's 20+ years of industry experience as an operator.

In addition to its wide-ranging traditional sports offering, Pinnacle Solution is also renowned for being the leading supplier in esports betting. Winning multiple awards has positioned Pinnacle Solution as the gold standard in B2B esports betting, proven to help clients take their product to the next level.

For further information, please contact:

Prit Singh Investor Relations at FansUnite
ir@fansunite.com
(905) 510-7636

Scott Burton Chief Executive Officer of FansUnite
scott@fansunite.com

Darius Eghdami President of FansUnite
darius@fansunite.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. 

FORWARD-LOOKING STATEMENTS: Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "believes," "belief," "expects," "intends," "anticipates," "potential," "should," "may," "will," "plans," "continue" or similar expressions to be uncertain and forward-looking. Forward-looking statements may include, without limitation, statements relating to future outlook and anticipated events such as: the leveraging of GameCo's US license infrastructure; GameCo becoming an official reseller of the platform; the Company's entrance into the US market and the Company's strategy with respect thereto; the importance of the US market to the Company; impacts of the GameCo/Askott partnership on the Company's success; the Company's ability to become a leading technology platform and a leader in the global I-gaming market, and to serve the gaming market; the potential growth of the Company and the gaming market; the increased number of betting options; the ability of the Company to scale its B2B arm and maintain its B2C platforms; the Company's unique portfolio of assets; and discussion of future plans, projections, objectives, estimates and forecasts and the timing related thereto. Forward-looking statements are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of FansUnite to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Additional information regarding the risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's Non-Offering Prospectus dated March 27, 2020 filed on its issuer profile on SEDAR at www.sedar.com and risks related to global pandemics, including the novel coronavirus (COVID-19) global health pandemic, and the spread of other viruses or pathogens and influence of macroeconomic developments. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The forward-looking statements in this news release are made as of the date of this release. FansUnite disclaims and does not undertake to update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/65230

News Provided by Newsfile via QuoteMedia

FansUnite CSE:FANS Emerging Tech Investing

Sona's Cancer Therapy Triggers Abscopal Effect, Eliminating Distant Tumors In Preclinical Melanoma Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that a detailed biomarker analysis of the recently reported pre-clinical melanoma study conducted at Dalhousie University (the "Study") indicates that, beyond shrinking tumors on its own, Sona's Targeted Hyperthermia Therapy ("THT") also stimulates the innate immune system to target and eliminate untreated (contralateral) tumors when combined with a standard immunotherapeutic drug, IL-2. (See figure #1, below.) On the basis of efficacy data achieved in two different murine cancer models (triple negative breast cancer and malignant melanoma), the Company is now proceeding with safety and biocompatibility testing that will be required by regulating agencies to enter into human studies.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

PRINCIPAL TECHNOLOGIES ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

Principal Technologies Inc. (the " Company ") (TSXV: PTEC) (FSE: J07), is pleased to announce the closing of the first tranche (" Tranche 1 ") of its previously announced non-brokered private placement (the " Offering ") with one investor, MRPT Invest UG (" MRPT "), a company owned and controlled by Markus Mair . The Company issued a total of 4,000,000 units at $0.25 per unit for gross proceeds of $1,000,000 . Each unit (a " Unit ") will consist of one common share (a ' Share ") of the Company and one common share purchase warrant (a " Warrant "). Each Warrant entitles the holder to purchase one additional Share of the Company at $0.30 for a period of two (2) years from the date of closing. The Warrants are subject to a blocker term that prohibits exercise of the Warrants to the extent the holder would as a result of any exercise exceed 19.99% of then issued Shares.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Sona's Therapy Shows Significant Preclinical Efficacy in Second Cancer

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that its targeted hyperthermia therapy ("THT") demonstrated positive results in a second preclinical cancer model. Findings just presented at the 2024 STING & TLR Targeted Therapies Summit for immunotherapies in San Diego, California, show that Sona's THT achieved responses in a preclinical melanoma model equal to that which was recently reported from its triple negative breast cancer study. THT effectively treated melanoma tumors in all animals when administered on its own. Further, when THT was combined with doses of interleukin-2 ("IL-2"), a standard immunotherapy, a synergistic effect was shown whereby greater treatment response, measured by tumor volume reduction, was achieved in comparison to either approach alone.